NASDAQ:IMVT

Immunovant Stock Insider Trading

Healthcare > Biotechnology

Buy IMVT

*Your capital is at risk

$38.70

-1.01 (-2.54%)

At Close: Jul 13, 2026

Immunovant Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 86.60. In total, the insiders bought 19.62M and sold 900.87K IMVT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	86.60
● Buy	19.62M shares
● Sell	900.87K shares
45% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence Jun 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 86.6. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 08, 2026 Sell	Common Stock S-Sale	Van Tuyl Christopher Chief Legal Officer	Officer	63 Value: $3K
Jul 08, 2026 Sell	Common Stock S-Sale	Van Tuyl Christopher Chief Legal Officer	Officer	1 143 Value: $45.2K
Jul 08, 2026 Sell	Common Stock S-Sale	Gloria Melanie Chief Operating Officer	C-Suite Officer	106 Value: $4K
Jul 08, 2026 Sell	Common Stock S-Sale	Gloria Melanie Chief Operating Officer	C-Suite Officer	1 930 Value: $76.3K
Jul 08, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	1 906 Value: $75.3K
Jul 08, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	105 Value: $4K
Jul 08, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	1 399 Value: $55.3K
Jul 08, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	77 Value: $3K
Jul 02, 2026 Sell	Common Stock S-Sale	Venker Eric Chief Executive Officer	CEO / President	3 092 Value: $119.0K
Jul 01, 2026 Sell	Common Stock D-Return	Venker Eric Chief Executive Officer	CEO / President	86 629 Value: $3.30M
Jul 01, 2026 Buy	Common Stock M-Exempt	Venker Eric Chief Executive Officer	CEO / President	92 188 Value: $1.33M
Jul 01, 2026 Buy	Capped Value Appreciation Rights M-Exempt	Venker Eric Chief Executive Officer	CEO / President	92 188 Value: $1.33M
Jun 26, 2026 Sell	Common Stock S-Sale	Pande Atul Director	Director	1 500 Value: $57.0K
Jun 26, 2026 Buy	Common Stock M-Exempt	Pande Atul Director	Director	1 500 Value: $12.6K
Jun 26, 2026 Buy	Common Stock M-Exempt	Van Tuyl Christopher Chief Legal Officer	Officer	17 824 Value: $270.9K
Jun 26, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	6 723 Value: $261.8K
Jun 26, 2026 Sell	Common Stock S-Sale	Stout Jay S Chief Technology Officer	Officer	33 277 Value: $1.27M
Jun 26, 2026 Sell	Common Stock S-Sale	Gloria Melanie Chief Operating Officer	C-Suite Officer	2 966 Value: $115.5K
Jun 26, 2026 Sell	Common Stock S-Sale	Gloria Melanie Chief Operating Officer	C-Suite Officer	14 748 Value: $563.1K
Jun 26, 2026 Sell	Common Stock S-Sale	Van Tuyl Christopher Chief Legal Officer	Officer	14 982 Value: $572.2K
Jun 26, 2026 Sell	Common Stock S-Sale	Van Tuyl Christopher Chief Legal Officer	Officer	2 842 Value: $110.7K
Jun 26, 2026 Buy	Stock Option (right to buy) M-Exempt	Van Tuyl Christopher Chief Legal Officer	Officer	17 824 Value: $270.9K
Jun 26, 2026 Buy	Stock Option (right to buy) M-Exempt	Girao Tiago Chief Financial Officer	C-Suite Officer	10 000 Value: $159.0K
Jun 26, 2026 Buy	Common Stock M-Exempt	Girao Tiago Chief Financial Officer	C-Suite Officer	10 000 Value: $159.0K
Jun 26, 2026 Sell	Common Stock S-Sale	Girao Tiago Chief Financial Officer	C-Suite Officer	10 000 Value: $384.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNOVANT, INC.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for...

Read Full Profile Here